Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Suncor Energy Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.08 (market cap $39.89B), while Suncor Energy Inc. trades at $60.77 (market cap $69.71B). The key difference: Suncor Energy Inc. is the larger of the two by market cap, and Suncor Energy Inc. pays a 2.85% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SU | |
|---|---|---|
Market Cap | $39.89B | $69.71B |
Sector | Health | Energy |
52-Week High | $491.22 | $69.73 |
52-Week Low | $278.09 | $38.17 |
Enterprise Value | $38.15B | $77.84B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Suncor Energy (SU) trades at $59.25, up 1.3% today, with strong analyst support (74% buy ratings) and bullish technical signals. The stock shows solid fundamentals with a P/E of 15.99, net margin of 11.62%, and consistent dividend payments. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 results exceeded forecasts. Cash flow remains positive with $166M net inflow in 2025.
Outlook remains positive with expected revenue growth to $54.5B in 2026 and improving profit margins. Key risks include oil price volatility and operational challenges. The stock presents value opportunity with attractive valuation metrics and strong institutional support, though investors should monitor Q2 2026 earnings results against the $2.26 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
